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At the end of 2015, ASEAN countries became 
closer to one another as part of the new AEC. 
Under the trade bloc’s economic integration 
arrangements, their citizens will ﬁnd it easier to 
do business in other ASEAN countries, import 
and export goods, and ﬁnd jobs in the region.
The negotiations and compromises leading 
up to the historic agreement, however, have also 
highlighted a growing issue – how trade treaties 
can affect people’s access to healthcare and 
medicines; in ways that are not always for 
the better.
Professor Locknie Hsu, at the SMU School of 
Law, is particularly interested in the intricacies of 
such treaties. She specialises in international 
trade and investment law, and is part of a working 
group of ASEAN representatives that seeks to 
facilitate cross-border trade by harmonising 
commercial laws across these countries.
“As ambitious agreements throw the 
connection between trade and health into even 
sharper relief, countries will have to grapple 
with the difficult task of balancing their desire 
for economic growth with ensuring affordable 
and accessible healthcare and medicines for 
their citizens,” she says.
BALANCING HEALTHCARE AND  
ECONOMIC GOALS
In a 2015 paper titled ‘Regulatory Flexibilities 
and Tensions in Public Health and Trade – 
An Asian Perspective’ published in the 
Asian Journal of WTO and International 
Health Law and Policy, Professor Hsu zeroes 
in on one particular, under-discussed issue of 
trade treaties, namely the tensions between 
governments’ economic and public health goals 
when they sit at the negotiating table.
During the discussions for the Trans-Paciﬁc 
Partnership (TPP) trade agreement, the US 
called for strong intellectual property protections 
for biologic medicines, which are expensive 
medicines derived from living organisms. The 
US wanted 12 years of data exclusivity for 
biologics makers, during which rivals would be 
blocked from creating ‘biosimilars’, or cheaper 
versions of the drug. In the end, a compromise 
provision was struck by negotiators. However, as 
President Donald Trump has decided to withdraw 
the US from the TPP agreement, its provisions 
have not been brought into effect.
But critics believe that too-stringent 
protections stifle competition and prevent 
affordable medicines from entering the market 
earlier. Australia, for instance, wanted just ﬁve 
years of data protection for biologics makers. 
The TPP text reveals a compromise that has 
been struck on the duration of protection.
“In an economically-diverse region such as 
Asia, which has both high-income countries and 
least-developed countries, it is not surprising that 
differences in health priorities and the ability of 
citizens to pay for medicines can also give rise to 
divergent trade, intellectual property and health 
laws and policies,” Professor Hsu notes.
Another potential issue in trade treaties is 
when Asian countries take differing approaches 
to compulsory licensing, she says. Compulsory 
licensing refers to when governments allow 
another company to manufacture a product 
without the patent owner’s consent, but with 
compensation. For example, a country may need 
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a potentially life-saving drug as quickly as possible 
but the patent holder may be unable or unwilling 
to meet the demand.
In recent years, India, Indonesia, Malaysia 
and Thailand have used compulsory licensing 
for patented pharmaceuticals, although not 
without some legal challenges by the patent 
holders. Thailand, in particular, has used 
compulsory licensing even for drugs to treat 
non-infectious diseases. Singapore, on the 
other hand, has announced that it will use 
compulsory licensing only in emergencies or 
extremely urgent situations.
BIG TOBACCO AND ASEAN
Aside from making sure the public has access to 
affordable medicines, governments also have to 
regulate harmful substances such as tobacco. 
This, too, can be a source of tension in trade 
discussions, Professor Hsu comments in a 
monograph chapter, ‘Tobacco Control in ASEAN’, 
published in the book The Global Tobacco 
Epidemic and the Law in 2014.
ASEAN countries use a variety of non-ﬁscal 
and ﬁscal tools such as excise taxes and value-
added, or goods and services taxes to control 
tobacco use among their citizens. While import 
tariffs have also been imposed, the ASEAN Free 
Trade Area, its Common Effective Preferential 
Tariff system, and the Trade in Goods Agreement 
have led to ASEAN members committing to a 
reduction or elimination of these import tariffs 
on tobacco products. Non-ﬁscal tools include 
packaging requirements and restrictions on the 
purchase of such products by minors.
Complicating matters is the fact that some 
ASEAN countries such as Indonesia, Malaysia, 
the Philippines and Thailand are also tobacco 
growers. In fact, the Thailand Tobacco Monopoly 
(TTM), a state enterprise, operates under the 
Ministry of Finance. Thai law previously granted 
TTM a monopoly to produce cigarettes within 
Thailand, but this changed following pressure 
from the country’s trade partners, including 
the US.
The tobacco issue was also a point of 
contention during the TPP negotiations. Some of 
the negotiating countries, such as the US and 
Japan, have strong private interests in tobacco 
production and export. Other countries 
such as Malaysia were adamant that the deal 
should not compromise governments’ ability to 
regulate tobacco use as part of public health 
protection efforts.
AN EVOLVING LANDSCAPE
As countries in Asia continue to negotiate 
new trade partnerships, tensions between 
healthcare and economic goals will continue to 
recur, Professor Hsu says. ASEAN countries, for 
instance, negotiated with six external trade 
partners to form the Regional Comprehensive 
Economic Partnership. Members of the 
Asia-Paciﬁc Economic Cooperation (APEC) also 
discussed how to create a Free Trade Area of 
the Asia Paciﬁc.
To smoothen the way for the negotiations, 
Asian trade partners should identify common 
interests and health priorities, and carry out 
health impact assessments for trade treaty 
provisions, Professor Hsu suggests. Her book, 
Trade, Investment, Innovation and their 
Impact on Access to Medicines: An Asian 
Perspective, published in February 2016 by 
Cambridge University Press, examines the issue 
in greater detail.
“As ASEAN evolves towards greater 
integration and development of a common 
voice on global issues, it will be particularly 
important to consider what that voice will 
say when negotiating trade and public health 
issues,” she shares. 
